정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 590 | Terminated | Safety in Convalescent Plasma Transfusion to COVID-19 | COVID-19 | Biological: Convalescent Plasma | Phase 1 | Hospital San Jose Tec de Monterrey, Tecnologico de Monterrey | OTHER | 12 | All | 18 Years | Hospital San Jose, Monterrey, Nuevo Leon, Mexico |
| 589 | Recruiting | Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia | Corona Virus Infection | Biological: T memory cells and NK cells | Phase 2 | Instituto de Investigacion Hospital Universitario La Paz, Universidad Autonoma de Madrid, Universidad Miguel Hernandez de Elche, Biocruces Bizkaia Health Research Institute, Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la Comunitat Valenciana | OTHER | 58 | All | ~ 80 Years | Hospital Universitario La Paz, Madrid, Spain |
| 588 | Active, not recruiting | Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents | COVID-19 | Biological: SARS-CoV-2 Inactivated Vaccine Biological: Placebo |
Phase 2 | Sinovac Research and Development Co., Ltd. | INDUSTRY | 500 | All | 3 Years ~ 17 Years | Zanhuang county Center for Disease Control and Prevention, Shijiazhuang, Hebei, China |
| 587 | Recruiting | Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults | COVID-19 | Biological: Experimental Group | Phase 4 | Sinovac Research and Development Co., Ltd. | INDUSTRY | 121000 | All | 18 Years | Yongping Center for Diseases Control and Prevention, Dali, Yunnan, China |
| 586 | Recruiting | Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents | COVID-19 | Biological: Experimental Group | Phase 4 | Sinovac Research and Development Co., Ltd. | INDUSTRY | 33000 | All | 3 Years ~ 17 Years | Yongping Center for Diseases Control and Prevention, Dali, Yunnan, China |
| 585 | Completed | Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers | Covid19 | Drug: UNI911 inhalation 1% and intranasal spray 1% Drug: Placebo |
Phase 1 | UNION therapeutics | INDUSTRY | 64 | All | 18 Years ~ 65 Years | DanTrials ApS, Copenhagen, Denmark |
| 584 | Withdrawn | Safety of T Regulatory Cell Therapy in Subjects With COVID-19 Induced Acute Respiratory Distress Syndrome | Covid19 | Biological: T regulatory cells | Phase 1 | Stanford University | OTHER | 0 | All | 18 Years ~ 75 Years | Stanford University, Stanford, California, United States |